ASHP Advantage: Where Do We Go from Here? Discussing the Future of Eosinophilic Esophagitis Treatment

Hear experts discuss the FDA’s recent Complete Response Letter CRL regarding Takeda’s budesonide oral solution for eosinophilic esophagitis (EoE), what therapies are in the pipeline for EoE and their potential role in therapy. 

 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.